Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). OncoSec Medical's share price for the quarter that ended in Jan. 2023 was $2.2. OncoSec Medical's Shares Outstanding (EOP) for the quarter that ended in Jan. 2023 was 2.97 Mil. Therefore, OncoSec Medical's market cap for the quarter that ended in Jan. 2023 was $6.54 Mil.
OncoSec Medical's quarterly market cap
declined
from Jul. 2022 ($28.36 Mil) to Oct. 2022 ($16.55 Mil) and
declined
from Oct. 2022 ($16.55 Mil) to Jan. 2023 ($6.54 Mil).
OncoSec Medical's annual market cap
declined
from Jul. 2020 ($96.83 Mil) to Jul. 2021 ($85.35 Mil) and
declined
from Jul. 2021 ($85.35 Mil) to Jul. 2022 ($28.36 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. OncoSec Medical's Enterprise Value for Today is $-0.22 Mil.
OncoSec Medical Market Cap Historical Data
The historical data trend for OncoSec Medical's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of OncoSec Medical's Market Cap
For the Biotechnology subindustry, OncoSec Medical's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoSec Medical's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoSec Medical's Market Cap distribution charts can be found below:
* The bar in red indicates where OncoSec Medical's Market Cap falls into.
OncoSec Medical Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
OncoSec Medical's Market Cap for the fiscal year that ended in Jul. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoSec Medical (OTCPK:ONCSQ) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
OncoSec Medical Market Cap Related Terms
Thank you for viewing the detailed overview of OncoSec Medical's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
OncoSec Medical (OncoSec Medical) Business Description
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ONCSQ has been successfully added to your 